Clinical trial results4
Persistence of efficacy was demonstrated for at least six months, with the two grade or better improvement from the first trial maintained in 92% of patients. No patients reverted back to baseline. Patient safety profile was also excellent, with very few related adverse events. Based on experience from current clinics, patients treated with Kleresca® Acne Treatment show results lasting up to a year or above.
"Study confirmed the long duration of effect following treatment"
"Patient safety profile was excellent, with very few related adverse events"
"Kleresca® Acne Treatment provides long-term efficacy and safety in the treatment of acne vulgaris, with a rate of compliance above what is generally observed in a young population"